The new building measuring 30,000 sq ft., located at Grifols’ industrial complex in Clayton, North Carolina (USA) will allow the company to increase its human plasma fractionation capacity in North America.
The fractionation plant will have twenty fully automated reactors as well as the corresponding equipment for separation of the different plasma fractions, and the automated production process cleaning equipment. Process safety and plant operation have been combined in the design of these installations by creating production areas that are integrated within the general flow of the factory.
The previously approved civil engineering Project will be completed next August and the rest of the production installations will be terminated during the first quarter of 2013.
In both cases, Grifols Engineering is well acquainted with all the applicable regulations, since the company has prior experience in designing and executing similar projects at other Grifols companies and projects that have required FDA and EMA approval. This will be the sixth plant of this nature that Grifols Engineering has handled.
Grifols Engineering’s experience in this type of biopharmaceutical installation means that the new plant will work with high standards of both quality and technology.